Biotech Values

[biomaven0]

I’m not aware of a generic-drug case where this has ever happened.

Nor am I - but then there have only been a handful of at-risk launches to date (with Teva's at-risk launch of Neurontin perhaps being the most prominent). Basically it's all a big poker game, with settlement being the most likely outcome by far.

Peter